 Nephrology Drugs Market Insights, Competitive Landscape, and Market Forecast - 2033
The global nephrology drugs market is growing steadily as kidney disease emerges as a major public health concern across developed and developing economies. The rising burden of diabetes, high bloo... もっと見る
※当ページの内容はウェブ更新時の情報です。
SummaryThe global nephrology drugs market is growing steadily as kidney disease emerges as a major public health concern across developed and developing economies. The rising burden of diabetes, high blood pressure, and obesity, combined with the introduction of therapies proven to slow disease progression, is significantly increasing demand for medicines used to treat renal disorders and related complications. The global nephrology drugs market is expected to be valued at US$ 24.50 Billion in 2026 and is projected to reach US$ 40.39 Billion by 2033, growing at a CAGR of 7.4% between 2026 and 2033.Market Insights: The nephrology drugs industry includes treatments for chronic kidney disease, diabetic kidney disease, glomerular disorders, renal anemia, secondary hyperparathyroidism, hyperphosphatemia, and electrolyte imbalances. Treatment practices have changed considerably with the introduction of sodium-glucose cotransporter-2 inhibitors and newer mineralocorticoid receptor antagonists that offer meaningful kidney protection. Specialized therapies addressing IgA nephropathy and other rare glomerular diseases are gaining approvals. Drug developers are focusing on large outcome studies, combination use, and targeted mechanisms. At the same time, generic entry across older phosphate binders and anemia treatments is shaping price competition in mature segments of the market. Drivers: The nephrology drugs market is primarily driven by the increasing global incidence of chronic kidney disease linked to diabetes, obesity, and hypertension. Demographic aging is expanding the population at risk of reduced kidney function. Compelling clinical trial data for kidney-protective drug classes is leading to updated treatment guidelines and higher prescription volumes. Expanded screening programs are supporting earlier detection and treatment. Moreover, health systems facing the substantial costs of dialysis and kidney transplantation are prioritizing therapies that delay progression, while approvals for rare kidney disease treatments are further broadening the market's commercial potential. Business Opportunity: Considerable opportunities exist for developers of disease-modifying treatments for glomerular diseases, autosomal dominant polycystic kidney disease, and other underserved renal conditions. Emerging mechanisms including complement pathway inhibitors, dual endothelin and angiotensin receptor antagonists, and genetic therapies are drawing substantial research investment. Fast-growing markets with large diabetic populations and improving medical infrastructure provide strong prospects for expansion. Digital adherence and remote monitoring solutions can enhance treatment outcomes. In addition, multi-pathway combination regimens and oral therapies for renal anemia offer opportunities to differentiate portfolios and reach broader patient populations. Region Analysis: North America dominates the nephrology drugs market, backed by high chronic kidney disease prevalence, rapid adoption of innovative kidney-protective medicines, and strong reimbursement coverage. Europe accounts for a significant share, supported by structured renal care services, evidence-based guidelines, and increasing use of newer drug classes. Asia Pacific is anticipated to grow at the fastest rate over the forecast period due to its vast diabetic population, expanding nephrology services, and rising healthcare investments in China, India, Japan, and Southeast Asia. Latin America shows steady progress as awareness and access to kidney disease treatments improve in Brazil, Mexico, and Colombia. The Middle East & Africa is advancing gradually amid high diabetes rates and growing renal care infrastructure. Key Players: • AstraZeneca plc • Bayer AG • Amgen Inc. • Vertex Pharmaceuticals Incorporated • GSK plc • Otsuka Pharmaceutical Co. Ltd. • Fresenius Medical Care AG & Co. KGaA • Novartis AG • Boehringer Ingelheim International GmbH • CSL Limited Segmentation: By Drug Class • Erythropoiesis-Stimulating Agents (ESAs) • SGLT2 Inhibitors • Phosphate Binders • Others By Indication • Chronic Kidney Disease (CKD) • End-Stage Renal Disease (ESRD)/Dialysis • Anemia of CKD • Others By Route of Administration • Oral • Injectable By Region • North America • Europe • Asia Pacific • Latin America • Middle East & Africa Table of Contents1. Executive Summary1.1. Global Nephrology Drugs Market Snapshot 1.2. Future Projections 1.3. Key Market Trends 1.4. Regional Snapshot, by Value, 2026 1.5. Analyst Recommendations 2. Market Overview 2.1. Market Definitions and Segmentations 2.2. Market Dynamics 2.2.1. Drivers 2.2.2. Restraints 2.2.3. Market Opportunities 2.3. Value Chain Analysis 2.4. COVID-19 Impact Analysis 2.5. Porter's Five Forces Analysis 2.6. Impact of Russia-Ukraine Conflict 2.7. PESTLE Analysis 2.8. Regulatory Analysis 2.9. Price Trend Analysis 2.9.1. Current Prices and Future Projections, 2025-2033 2.9.2. Price Impact Factors 3. Global Nephrology Drugs Market Outlook, 2020-2033 3.1. Global Nephrology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 3.1.1. Erythropoiesis-Stimulating Agents (ESAs) 3.1.2. SGLT2 Inhibitors 3.1.3. Phosphate Binders 3.1.4. Others 3.2. Global Nephrology Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033 3.2.1. Chronic Kidney Disease (CKD) 3.2.2. End-Stage Renal Disease (ESRD)/Dialysis 3.2.3. Anemia of CKD 3.2.4. Others 3.3. Global Nephrology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 3.3.1. Oral 3.3.2. Injectable 3.4. Global Nephrology Drugs Market Outlook, by Region, Value (US$ Bn), 2020-2033 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Latin America 3.4.5. Middle East & Africa 4. North America Nephrology Drugs Market Outlook, 2020-2033 4.1. North America Nephrology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 4.1.1. Erythropoiesis-Stimulating Agents (ESAs) 4.1.2. SGLT2 Inhibitors 4.1.3. Phosphate Binders 4.1.4. Others 4.2. North America Nephrology Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033 4.2.1. Chronic Kidney Disease (CKD) 4.2.2. End-Stage Renal Disease (ESRD)/Dialysis 4.2.3. Anemia of CKD 4.2.4. Others 4.3. North America Nephrology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 4.3.1. Oral 4.3.2. Injectable 4.4. North America Nephrology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 4.4.1. U.S. Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 4.4.2. U.S. Nephrology Drugs Market Outlook, by Indication, 2020-2033 4.4.3. U.S. Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 4.4.4. Canada Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 4.4.5. Canada Nephrology Drugs Market Outlook, by Indication, 2020-2033 4.4.6. Canada Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 4.5. BPS Analysis/Market Attractiveness Analysis 5. Europe Nephrology Drugs Market Outlook, 2020-2033 5.1. Europe Nephrology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 5.1.1. Erythropoiesis-Stimulating Agents (ESAs) 5.1.2. SGLT2 Inhibitors 5.1.3. Phosphate Binders 5.1.4. Others 5.2. Europe Nephrology Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033 5.2.1. Chronic Kidney Disease (CKD) 5.2.2. End-Stage Renal Disease (ESRD)/Dialysis 5.2.3. Anemia of CKD 5.2.4. Others 5.3. Europe Nephrology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 5.3.1. Oral 5.3.2. Injectable 5.4. Europe Nephrology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 5.4.1. Germany Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 5.4.2. Germany Nephrology Drugs Market Outlook, by Indication, 2020-2033 5.4.3. Germany Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 5.4.4. Italy Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 5.4.5. Italy Nephrology Drugs Market Outlook, by Indication, 2020-2033 5.4.6. Italy Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 5.4.7. France Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 5.4.8. France Nephrology Drugs Market Outlook, by Indication, 2020-2033 5.4.9. France Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 5.4.10. U.K. Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 5.4.11. U.K. Nephrology Drugs Market Outlook, by Indication, 2020-2033 5.4.12. U.K. Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 5.4.13. Spain Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 5.4.14. Spain Nephrology Drugs Market Outlook, by Indication, 2020-2033 5.4.15. Spain Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 5.4.16. Russia Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 5.4.17. Russia Nephrology Drugs Market Outlook, by Indication, 2020-2033 5.4.18. Russia Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 5.4.19. Rest of Europe Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 5.4.20. Rest of Europe Nephrology Drugs Market Outlook, by Indication, 2020-2033 5.4.21. Rest of Europe Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 5.5. BPS Analysis/Market Attractiveness Analysis 6. Asia Pacific Nephrology Drugs Market Outlook, 2020-2033 6.1. Asia Pacific Nephrology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 6.1.1. Erythropoiesis-Stimulating Agents (ESAs) 6.1.2. SGLT2 Inhibitors 6.1.3. Phosphate Binders 6.1.4. Others 6.2. Asia Pacific Nephrology Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033 6.2.1. Chronic Kidney Disease (CKD) 6.2.2. End-Stage Renal Disease (ESRD)/Dialysis 6.2.3. Anemia of CKD 6.2.4. Others 6.3. Asia Pacific Nephrology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 6.3.1. Oral 6.3.2. Injectable 6.4. Asia Pacific Nephrology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 6.4.1. China Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 6.4.2. China Nephrology Drugs Market Outlook, by Indication, 2020-2033 6.4.3. China Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 6.4.4. Japan Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 6.4.5. Japan Nephrology Drugs Market Outlook, by Indication, 2020-2033 6.4.6. Japan Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 6.4.7. South Korea Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 6.4.8. South Korea Nephrology Drugs Market Outlook, by Indication, 2020-2033 6.4.9. South Korea Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 6.4.10. India Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 6.4.11. India Nephrology Drugs Market Outlook, by Indication, 2020-2033 6.4.12. India Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 6.4.13. Southeast Asia Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 6.4.14. Southeast Asia Nephrology Drugs Market Outlook, by Indication, 2020-2033 6.4.15. Southeast Asia Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 6.4.16. Rest of SAO Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 6.4.17. Rest of SAO Nephrology Drugs Market Outlook, by Indication, 2020-2033 6.4.18. Rest of SAO Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 6.5. BPS Analysis/Market Attractiveness Analysis 7. Latin America Nephrology Drugs Market Outlook, 2020-2033 7.1. Latin America Nephrology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 7.1.1. Erythropoiesis-Stimulating Agents (ESAs) 7.1.2. SGLT2 Inhibitors 7.1.3. Phosphate Binders 7.1.4. Others 7.2. Latin America Nephrology Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033 7.2.1. Chronic Kidney Disease (CKD) 7.2.2. End-Stage Renal Disease (ESRD)/Dialysis 7.2.3. Anemia of CKD 7.2.4. Others 7.3. Latin America Nephrology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 7.3.1. Oral 7.3.2. Injectable 7.4. Latin America Nephrology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 7.4.1. Brazil Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 7.4.2. Brazil Nephrology Drugs Market Outlook, by Indication, 2020-2033 7.4.3. Brazil Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 7.4.4. Mexico Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 7.4.5. Mexico Nephrology Drugs Market Outlook, by Indication, 2020-2033 7.4.6. Mexico Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 7.4.7. Argentina Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 7.4.8. Argentina Nephrology Drugs Market Outlook, by Indication, 2020-2033 7.4.9. Argentina Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 7.4.10. Rest of LATAM Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 7.4.11. Rest of LATAM Nephrology Drugs Market Outlook, by Indication, 2020-2033 7.4.12. Rest of LATAM Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 7.5. BPS Analysis/Market Attractiveness Analysis 8. Middle East & Africa Nephrology Drugs Market Outlook, 2020-2033 8.1. Middle East & Africa Nephrology Drugs Market Outlook, by Drug Class, Value (US$ Bn), 2020-2033 8.1.1. Erythropoiesis-Stimulating Agents (ESAs) 8.1.2. SGLT2 Inhibitors 8.1.3. Phosphate Binders 8.1.4. Others 8.2. Middle East & Africa Nephrology Drugs Market Outlook, by Indication, Value (US$ Bn), 2020-2033 8.2.1. Chronic Kidney Disease (CKD) 8.2.2. End-Stage Renal Disease (ESRD)/Dialysis 8.2.3. Anemia of CKD 8.2.4. Others 8.3. Middle East & Africa Nephrology Drugs Market Outlook, by Route of Administration, Value (US$ Bn), 2020-2033 8.3.1. Oral 8.3.2. Injectable 8.4. Middle East & Africa Nephrology Drugs Market Outlook, by Country, Value (US$ Bn), 2020-2033 8.4.1. GCC Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 8.4.2. GCC Nephrology Drugs Market Outlook, by Indication, 2020-2033 8.4.3. GCC Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 8.4.4. South Africa Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 8.4.5. South Africa Nephrology Drugs Market Outlook, by Indication, 2020-2033 8.4.6. South Africa Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 8.4.7. Egypt Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 8.4.8. Egypt Nephrology Drugs Market Outlook, by Indication, 2020-2033 8.4.9. Egypt Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 8.4.10. Nigeria Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 8.4.11. Nigeria Nephrology Drugs Market Outlook, by Indication, 2020-2033 8.4.12. Nigeria Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 8.4.13. Rest of Middle East Nephrology Drugs Market Outlook, by Drug Class, 2020-2033 8.4.14. Rest of Middle East Nephrology Drugs Market Outlook, by Indication, 2020-2033 8.4.15. Rest of Middle East Nephrology Drugs Market Outlook, by Route of Administration, 2020-2033 8.5. BPS Analysis/Market Attractiveness Analysis 9. Competitive Landscape 9.1. Company Vs Segment Heatmap 9.2. Company Market Share Analysis, 2025 9.3. Competitive Dashboard 9.4. Company Profiles 9.4.1. AstraZeneca plc 9.4.1.1. Company Overview 9.4.1.2. Product Portfolio 9.4.1.3. Financial Overview 9.4.1.4. Business Strategies and Developments 9.4.2. Bayer AG 9.4.3. Amgen Inc. 9.4.4. Vertex Pharmaceuticals Incorporated 9.4.5. GSK plc 9.4.6. Otsuka Pharmaceutical Co. Ltd. 9.4.7. Fresenius Medical Care AG & Co. KGaA 9.4.8. Novartis AG 9.4.9. Boehringer Ingelheim International GmbH 9.4.10. CSL Limited 10. Appendix 10.1. Research Methodology 10.2. Report Assumptions 10.3. Acronyms and Abbreviations
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野（医薬）の最新刊レポート
Fairfield Market Research社の 医薬品・バイオテクノロジー分野 での最新刊レポート
本レポートと同じKEY WORD（landscape）の最新刊レポート
よくあるご質問Fairfield Market Research社はどのような調査会社ですか?Fairfield Market Researchでは、最新かつ最も関連性の高い市場データと洞察に満ちた詳細なレポートを発行しています。広範囲にわたり、業界動向や市場ベースのデータを含んでおり、顧客が... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-４日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書（必要に応じて納品書も）を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
|
